The global flow cytometry in oncology market was valued at USD 2333.36 million in 2024 and is anticipated to grow from USD 2613.36 million in 2025 to reach USD 6470.59 million by 2033, expanding at a strong CAGR of 12% during the forecast period. Flow cytometry is revolutionizing cancer diagnostics by enabling quantitative detection and measurement of cancerous cell characteristics. While its role in hematological malignancies is well established, ongoing research is expanding its utility in solid tumor assessment as well.
? Download Sample Report
Market Drivers Supporting Growth
Increasing Fund Infusions for Hematological Malignancies
The oncology landscape is witnessing substantial research funding from both public and private organizations to advance flow cytometry applications. For example, the Leukemia and Lymphoma Society (LLS) invested USD 13.8 million in 2019 to support pediatric blood cancer research at leading institutions like Johns Hopkins University and the University of Michigan. Similarly, the Leukemia Research Foundation provided USD 1.2 million to investigators across the U.S. and Japan to drive advancements in cancer diagnostics. Such investments are fueling innovation, particularly in next-generation flow cytometry-based testing products, accelerating market growth.
Rising Incidence of Hematological Malignancies
The global incidence of blood cancers such as leukemia, lymphoma, and multiple myeloma is steadily increasing, driven by aging populations, lifestyle factors, and compromised immune systems. According to the Global Cancer Observatory, multiple myeloma incidence was 2.1 cases in males and 1.4 cases in females per 100,000 people in 2018, with mortality rates of 1.1 cases per 100,000 people. As physicians prioritize early detection and minimal residual disease (MRD) testing to predict relapse risk, the adoption of flow cytometry-based diagnostics is rising sharply, strengthening the market outlook.
Restraining Factor: False Positives and Negatives
Despite its promise, flow cytometry faces challenges with false positives and negatives in MRD testing. Sub-optimal detection of residual cells may lead to inaccurate clinical outcomes, undermining therapy protocols. The absence of standardized trial data also limits the ability to establish high-specificity assays. These concerns are key barriers to broader adoption, highlighting the need for improved test precision.
Market Opportunity: Multiparametric Flow Cytometry
One of the most exciting opportunities lies in multiparametric flow cytometry (MFC), which integrates immunophenotypic, morphologic, and genotypic profiling of cancer cells. MFC allows highly sensitive MRD detection (up to 10-4 cells) and supports precision medicine strategies. Its ability to identify disease subtypes and refine relapse assessments is positioning MFC as a transformative tool in hematologic oncology diagnostics.
Regional Insights
North America leads the market, expected to grow at a CAGR of 10.9%. The presence of legacy diagnostic companies, rising adoption of next-generation products, and high prevalence of hematological cancers are driving dominance in the U.S.
Europe follows closely with a CAGR of 12.12%. Initiatives like the Cancer Diagnostic and Treatment for All program (2021) and the European Initiative to Understand Cancer are enhancing access to innovative technologies, making Europe a key growth hub.
Asia-Pacific is in an intense growth phase, supported by rising healthcare investments, emerging startups, and collaborative consortiums. However, uneven economic development across countries remains a challenge.
Segmental Highlights
By Product Type: Assays and kits dominate, expected to grow at 12.4% CAGR, driven by rising testing requirements for hematological cancers.
By Technology: Cell-based flow cytometry holds the largest share, expanding at 11.5% CAGR due to its high clinical applicability in early cancer detection and targeted therapies.
By Cancer Type: Hematological malignancies lead the segment with a 12.8% CAGR, supported by growing diagnostic demand and incidence rates.
By Application: Translational research is a key application area, forecasted to grow at 11.4% CAGR, reflecting increased government initiatives in cancer R&D.
By End-User: Diagnostic laboratories dominate with a 12.6% CAGR, as they play a critical role in MRD testing and physician-laboratory partnerships for advanced cancer diagnostics.
Key Players in the Flow Cytometry in Oncology Market
Leading companies are actively innovating to strengthen their market positions. Prominent players include:
Agilent Technologies, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Cytek Biosciences
Danaher Corporation
Miltenyi Biotec B.V. & Co. KG
Thermo Fisher Scientific Inc.
Sony Corporation
NeoGenomics Laboratories Inc.
Luminex Corporation
Notable recent developments include Agilent Technologies’ 2023 partnership with Proscia to integrate digital pathology solutions, and bioAffinity Technologies’ commercialization initiatives to expand its CyPath® Lung brand in cancer diagnostics. These moves highlight the competitive push toward integrated and advanced oncology solutions.
Conclusion
The flow cytometry in oncology market is poised for remarkable growth, driven by research funding, rising cancer incidence, and breakthroughs in multiparametric testing. While challenges like false MRD results persist, ongoing innovation and global initiatives are unlocking new opportunities for precision diagnostics and patient-centric cancer care. With a projected CAGR of 12%, this market represents a critical frontier in oncology diagnostics, attracting investments and technological advancements across regions.
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI. Whether you are looking at business sectors in the next town or across continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
? Phone: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
? Email: sales@straitsresearch.com
